Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids

Table 3 Circulating noncoding RNA in pancreatic cancer

Ref.	Sample	Candidate target	Potential value
		miRNA
Wang et al[102], 2009	Plasma	miR-210 (↑), miR-21 (↑), miR-155 (↑), miR-196a (↑)	D
Ho et al[134], 2010	Plasma	miR-210 (↑)	D
Li et al[135], 2010	Plasma	miR-200a (↑), miR-200b (↑)	D
Ali et al[136], 2010	Plasma	miR-21 (↑)	D/P
Kong et al[105], 2011	Serum	miR-196a (↑)	D/S/P
LaConti et al[137], 2011	Serum	miR-155 (↑)	D
Morimura et al[138], 2011	Plasma	miR-18a (↑)	D
Liu et al[139], 2012	Serum	miR-16 (↑), miR-196a (↑)	D
Liu et al[140], 2012	Serum	miR-20a (↑), miR-21 (↑), miR-24 (↑), miR-25 (↑),	D/P
		miR-99a (↑), miR-185 (↑), miR-191 (↑)
Li et al[141], 2012	Serum	miR-1290 (↑)	D
Wang et al[142], 2013	Whole blood	miR-27a-3p (↑)	D
Kawaguchi et al[143], 2013	Plasma	miR-221 (↑), miR-375 (↓)	D/S
Zhao et al[144], 2013	Serum	miR-192 (↑)	D
Li et al[141], 2013	Serum	miR-1290 (↑)	D
Wang et al[145], 2013	Serum	miR-21 (↑)	T/P
Carlsen et al[146], 2013	Plasma	miR-375 (↑)	D
Que et al[147], 2013	Serum	miR-17-5p (↑), miR-21 (↑), miR-155 (↓), miR-196a (↓)	D/S
Schultz et al[103], 2014	Whole blood	Multigene index	D
Gao et al[148], 2014	Plasma	miR-16 (↑)	D
Chen et al[149], 2014	Plasma	miR-182 (↑)	D/S/P
Ganepola et al[150], 2015	Plasma	miR-22 (↑), miR-642b (↑), miR-885-5p (↑)	D
Abue et al[151], 2015	Plasma	miR-21 (↑), miR-483-3p (↑)	D/S/P
Slater et al[152], 2015	Serum	miR-196a (↑), miR-196b (↑)	D
Kojima et al[104], 2015	Serum	Multigene index	D
Xu et al[153], 2015	Plasma	miR-486-5p (↑), miR-938 (↑)	D
Madhavan et al[154], 2015	Serum	miR-1246 (↑), miR-3976 (↑), miR-4306 (↑), miR-4644 (↑)	D
Komatsu et al[123], 2015	Plasma	miR-223 (↑)	D/P
Miyamae et al[106], 2015	Plasma	miR-744 (↑)	D/S/P/T
		Other noncoding RNAs
Wang et al[117], 2015	Plasma	HOTTIP-005 (↑), RP11-567G11.1 (↑)	D/P
Baraniskin et al[155], 2013	Plasma/serum	U2 snRNA (↑)	D

D: Diagnostic marker; miRNA: MicroRNA; P: Prognostic marker; S: Staging marker; T: Treatment marker.